NCT05380492进行中（未招募）1 期
Phase 1/2a Dose Escalation Study of VOY-101 in Patients With Advanced Non-Neovascular Age-Related Macular Degeneration
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 45
- 试验地点
- 6
- 主要终点
- Safety Endpoints
研究概览
简要总结
This safety study comprises a dose escalation study of VOY-101, followed by a cohort of subjects randomized to the maximum tolerated dose arm, a lower dose arm, and control arm.
详细描述
This is a prospective, multi-center safety phase 1/2a study to evaluate the safety of a single, unilateral intravitreal (IVT) injection of three dose levels of VOY-101 therapy in subjects with late-stage non-neovascular age-related macular degeneration (AMD).
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Sequential
- 主要目的
- Treatment
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
盲法说明
The Phase 1 cohorts will be open-label, the Phase 2a cohort will be masked.
入排标准
- 年龄范围
- 50 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Are ≥50 years of age at the time of consent.
- •Are willing and able to understand and provide written informed consent.
- •Are willing and able to return for scheduled treatment and follow-up examinations.
- •Are able to undergo ETDRS BCDVA testing and ophthalmic imaging.
- •Well-demarcated GA secondary to AMD in the absence of MNV and in the absence of history of MNV.
- •Absence of signs of non-exudative MNV.
- •Additional Ocular Inclusion Criteria
- •Meet certain genotype criteria for risk of AMD.
排除标准
- •Are women of childbearing potential (WOCBP) and are pregnant or unwilling to use and document use of effective contraception for the duration of the study.
- •Additional Systemic, Ocular, and Genetic Exclusion Criteria.
结局指标
主要结局
Safety Endpoints
时间窗: Through 24 months
1\. Frequency of ocular and systemic adverse events (AEs) (serious \[SAEs\] and treatment-emergent non-serious adverse events \[TEAEs\])
次要结局
未报告次要终点
研究者
研究点 (6)
Loading locations...
相似试验
进行中（未招募）
1 期
Study of VOY-101 in Patients With Advanced Non-Neovascular Age-Related Macular DegenerationNon-neovascular Age-related Macular DegenerationAge-Related Macular DegenerationNCT06087458Perceive Biotherapeutics, Inc.60
已完成
1 期
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Study of VAY736 in Rheumatoid Arthritis PatientsRheumatoid ArthritisNCT02675803Novartis Pharmaceuticals65
终止
1 期
A Study of AbGn-107 in Patients With Gastric, Colorectal, Pancreatic or Biliary CancerGastric CancerBiliary CancerPancreatic CancerColorectal CancerNCT02908451AbGenomics B.V Taiwan Branch39
已完成
1 期
A Phase I/II Trial of VB-111 and Paclitaxel for Recurrent Platinum-Resistant Müllerian CancerPlatinum Resistant Ovarian CancerNCT01711970Vascular Biogenics Ltd. operating as VBL Therapeutics38
招募中
1 期
Dose Escalation Phase 1 Study of IOA-289 in combination with gemcitabine/nab-paclitaxel2024-515674-27-00iOnctura SA16